Magazine Article | October 3, 2022

What Has Changed With The R&D Tax Credit?

Source: Life Science Leader

By Yair Holtzman

According to the Congressional Budget Office, the pharmaceutical industry devoted $83 billion to R&D expenditures in 2019.

Those expenditures covered a variety of activities, including discovering and testing new drugs, genome sequencing developing incremental innovations such as product extensions, and clinical testing for safety-monitoring or marketing purposes. The amount spent is about 10 times what the industry spent per year in the 1980s, after adjusting for the effects of inflation. Below is a small sample of potentially qualifying projects and activities driving the industry in 2022.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader